News
After 24 weeks, those proportions reached 74.1% and 64.9% respectively, with the tolerability profile of the drug consistent with the phase 2 FRONTIER 1 and 2 studies reported last year.
FT Balanced Income Equity & ETF 68 CA 8.41 FT Balanced Income Equity & ETF 68 F CA 8.41 FT Balanced Income Equity & ETF 68 RE 8.41 FT Balanced Income Equity & ETF 68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback